The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > CeNeS Pharmaceuticals, Inc.

CeNeS Pharmaceuticals, Inc.
 PROFILE
CeNeS Pharmaceuticals, Inc. (formerly Cambridge NeuroScience) discovers and develops drugs focused on nerve cell survival and function. The company concentrates on two complementary technologies: growth-factor proteins, used to counteract nerve degeneration caused by diseases like multiple sclerosis and peripheral neuropathies; and ion-channel blockers, used to prevent nerve-cell death after stroke, and for treatment of glaucoma, Parkinson's and Alzheimer's diseases, and neuropathic pain. The firm acquired from Harvard University the exclusive license to Neuregulin, a growth factor intended for the treatment of neurodegenerative diseases. UK-based CeNeS Pharmaceuticals plc bought the company.

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 1.40
1-Yr. Sales Growth: (66.5)%
Employees: 17
Revenue per employee: $82,352.94

 KEY PEOPLE
• Robert N. McBurney
    CEO
• Glenn A. Shane
    CFO

 CONTACT INFO
333 Providence Hwy.
Norwood, MA 02062
US
Phone: 781-255-6700
Fax: 781-255-6711
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001